Please use this identifier to cite or link to this item: http://hdl.handle.net/10316/11856
DC FieldValueLanguage
dc.contributor.authorCustódio, Sofia-
dc.contributor.authorSaleiro, Sofia-
dc.contributor.authorDias, Margarida-
dc.contributor.authorFreire-de-Oliveira, Carlos-
dc.date.accessioned2009-10-29T09:10:02Z-
dc.date.available2009-10-29T09:10:02Z-
dc.date.issued2009-
dc.identifier.citationActa Obstétrica e Ginecológica Portuguesa. 3:1 (2009) 17-23en_US
dc.identifier.issn1646-5830-
dc.identifier.urihttp://hdl.handle.net/10316/11856-
dc.description.abstractIntroduction: Breast conserving therapy involves conservative surgery – excision of the tumor mass with negative surgical margins – followed by post-operative radiation therapy. The objective of this study was to assess the clinical results of breast conserving therapy in invasive cancer. Study design: Retrospective observational study. Material and Methods: Analysis of 231 patients with invasive breast cancer treated by conservative surgery in a tertiary care University Hospital over 11 years. Results: Average age at time of diagnosis was 55.2 years (23-87). Most patients (64.5%) were post-menopausal. Almost all patients presented with a suspicious nodule at radiologic examination (61.5%). No palpable lesions were found in 40.7% of patients. Clinical stage I was the most prevalent (82.7%) and most patients were biopsed guided by radiologic methods. The majority of patients (79.2%) was treated with lumpectomy /quadrantectomy and axillary lymph node excision. The most frequent histologic type was invasive ductal carcinoma, diagnosed in 69.2% of patients. In 73.6% of cases there was no evidence of lymph node metastases. Estrogen receptors were positive in 68.8% and CerbB2 was positive in 37.2%. Surgical margins were negative in 92.2%. Adjuvant therapy consisted of radiotherapy in 95%, hormonal therapy in 69.7% and chemotherapy in 48%, either alone or in association. Average time of follow-up was 66.6 months. During this period, 11 patients had local recurrence and 16 had distant metastases. Overall survival was 93.5% at 140 months and disease-free survival was 71.3% at 140 months. Conclusion: Conservative treatment appears to be a viable therapeutic option for invasive stage I and II breast cancer.en_US
dc.language.isoporen_US
dc.publisherFederação das Sociedades Portuguesas de Obstetrícia e Ginecologiaen_US
dc.rightsopenAccessen_US
dc.titleTratamento conservador do cancro da mama invasivo - avaliação de 11 anosen_US
dc.title.alternativeBreast conserving therapy in invasive breast cancer - 11 years of follow-upen_US
dc.typearticleen_US
item.languageiso639-1pt-
item.grantfulltextopen-
item.fulltextCom Texto completo-
Appears in Collections:FMUC Medicina - Artigos em Revistas Nacionais
Files in This Item:
File Description SizeFormat
Tratamento conservador do cancro da mama invasivo.pdf330.46 kBAdobe PDFView/Open
Show simple item record

Page view(s)

203
checked on Oct 1, 2019

Download(s) 50

289
checked on Oct 1, 2019

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.